There’s no reason to suspect that samples in the Kiel study would be representative of a different condition from Baylor. Regardless, to assuage your concerns:
Separate studies using separate groups of patients have already turned up very similar findings. See penile vascular abnormalities in Khera 2020 and Carlisle 2022. Also see alterations in neurosteroids in Caruso 2015 & Melcangi 2017 and differential expression of neurosteroid-involved genes in Howell 2021, aka Baylor.
Additionally, the Kiel study will measure androgen receptor (AR) expression, which two separate studies (Di Loreto 2014 and Howell 2021, aka Baylor) have shown to be overexpressed in PFS patients. So, we will have that point of comparison.
Lastly, if that occurred one would expect there to be intragroup sample differences in the Kiel study, as it would be implausible that all twelve samples were somehow representative of the same different condition.
So again, it’s basically impossible that could happen, and we would have several indicators if so. Given the constrained resources our community has and our shared interest of getting out of this as quickly as possible, it’s very important we shift focus from the what (Baylor, some current studies) to the why (Kiel).